Global Diabetic Retinopathy Market to Cross $ 12 Bn by 2025

February 25, 2020


As per the report titled ‘Diabetic Retinopathy Market Size By Type (Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy), By Age Group (40-49, 50-64, 65-74), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Distribution Channel (Hospitals & Pharmacies, Eye Clinics, Ambulatory Surgical Centers (ASCs)), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, India, China, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE), Application Potential, Competitive Market Share & Forecast, 2019 - 2025’ available with Market Study Report LLC, the global diabetic retinopathy market is projected to surpass USD 12 billion by the year 2025.
 

Rising prevalence of diabetes across the world is driving the growth of diabetic retinopathy market. Increasing demand for medications and ophthalmic surgical procedures is positively impacting the market growth. Introduction of advanced treatment solutions such as direct injections, intravitreal antiangiogenesis, and anti-inflammatory agents will enhance the business outlook in the coming years.  On the other hand, post-surgical complications associated with certain surgical production for diabetic retinopathy will hamper the market growth during the forecast period.
 

Based on the type, proliferative diabetic retinopathy segment is anticipated to grow by 7.5% through 2025. It is the most advanced phase of diabetic eye disease and can result in severe vision disorder. Growing need for effective treatment in tandem with increasing geriatric population who are susceptible to proliferative diabetic retinopathy are boosting the segment growth.
 

By age group, 40-49 age group segment accounted for USD 3 billion in 2018 and is expected to show a considerable growth during the study period. Individuals in this age group are highly prone to chronic diseases like diabetes due to unhealthy lifestyle. This factor along with rising number of diabetic patients in this age bracket are driving the diabetic retinopathy market.  
 

In terms of management procedure, the report cites that laser surgery segment is presumed to register 9.2% CAGR over the forecast timeline. Rising inclination towards minimally invasive procedures among the geriatric population in tandem with low post-surgical complications and less recovery time are supporting the demand for laser surgery.
 

Speaking of the distribution channel, ambulatory surgical centers (ASCs) segment was worth USD 2 billion in 2018 and is expected to grow momentously during the analysis period. Diabetic retinopathy treatments are generally performed on outpatient basis which incur low costs and have shorter recovery period as compared to other settings. These factors coupled with favorable reimbursement policies are fueling the segment growth.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/467733/
 

Considering the geographical outlook, diabetic retinopathy market in North America was worth USD 3 billion in 2018 and is presumed to exhibit a sizeable growth during 2019-2025. Increasing prevalence of diabetes among elderly population base is boosting the demand for advanced medications in the region. In addition, increasing awareness regarding minimally invasive ophthalmic surgeries will augment the regional growth in the years to come.
 

The major players of diabetic retinopathy market are BCN Peptides, Regeneron Pharmaceuticals, Kowa Company, Novartis, Allergan and Bayer AG, Ampio Pharmaceuticals, Alimera Sciences, and ThromboGenics.


Frequently Asked Questions (FAQ) :

Rising prevalence of diabetes across the world is driving the growth of diabetic retinopathy market. Increasing demand for medications and ophthalmic surgical procedures is positively impacting the market growth. Introduction of advanced treatment solutions such as direct injections, intravitreal antiangiogenesis, and anti-inflammatory agents will enhance the business outlook in the coming years.
Laser surgery segment of diabetic retinopathy market is presumed to register 9.2% CAGR over 2019-2025. Rising inclination towards minimally invasive procedures among the geriatric population in tandem with low post-surgical complications and less recovery time are supporting the demand for laser surgery.
Diabetic retinopathy market in North America was worth USD 3 billion in 2018 and is presumed to exhibit a sizeable growth during 2019-2025. Increasing prevalence of diabetes among elderly population base is boosting the demand for advanced medications in the region. In addition, increasing awareness regarding minimally invasive ophthalmic surgeries will augment the regional growth in the years to come.
The major players of diabetic retinopathy market are BCN Peptides, Regeneron Pharmaceuticals, Kowa Company, Novartis, Allergan and Bayer AG, Ampio Pharmaceuticals, Alimera Sciences, and ThromboGenics.